ResMed (NYSE: RMD, ASX: RMD) announced Monday that it signed a definitive agreement to acquire post-acute software provider MatrixCare for $750 million. “We were looking for another great addition to add a third leg, if you like, to the stool of our out-of-hospital software investments, and MatrixCare just came straight to the top,” ResMed CEO Mick […]
By continuing to use the site, you agree to the use of cookies. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. For more information, see our cookie policy.
